| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Echocardiography | 16 | 2021 | 1219 | 2.850 |
Why?
|
| Heart Diseases | 13 | 2024 | 722 | 2.100 |
Why?
|
| Ventricular Function, Left | 8 | 2022 | 559 | 1.200 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2022 | 398 | 1.200 |
Why?
|
| Heart Ventricles | 7 | 2023 | 835 | 1.190 |
Why?
|
| Echocardiography, Transesophageal | 5 | 2019 | 289 | 1.170 |
Why?
|
| Anthracyclines | 6 | 2024 | 339 | 1.040 |
Why?
|
| Neoplasms | 23 | 2024 | 15933 | 1.000 |
Why?
|
| Cardiovascular Diseases | 8 | 2022 | 2221 | 0.910 |
Why?
|
| Heart Neoplasms | 3 | 2018 | 209 | 0.880 |
Why?
|
| Atrial Flutter | 1 | 2023 | 34 | 0.860 |
Why?
|
| Cardiovascular System | 2 | 2023 | 142 | 0.810 |
Why?
|
| Stroke Volume | 7 | 2022 | 545 | 0.800 |
Why?
|
| Cardiotoxicity | 9 | 2024 | 152 | 0.710 |
Why?
|
| Heart Function Tests | 2 | 2019 | 73 | 0.680 |
Why?
|
| Atrial Fibrillation | 3 | 2023 | 727 | 0.660 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2018 | 12 | 0.630 |
Why?
|
| Cardiology | 4 | 2020 | 513 | 0.620 |
Why?
|
| Tachycardia, Sinus | 1 | 2016 | 12 | 0.560 |
Why?
|
| Endocarditis | 2 | 2021 | 126 | 0.550 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2018 | 67 | 0.530 |
Why?
|
| Rural Population | 1 | 2018 | 292 | 0.530 |
Why?
|
| Recovery of Function | 2 | 2016 | 686 | 0.510 |
Why?
|
| Pericardial Effusion | 4 | 2019 | 123 | 0.500 |
Why?
|
| Thrombosis | 2 | 2018 | 743 | 0.500 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 231 | 0.480 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2015 | 37 | 0.480 |
Why?
|
| Pericarditis | 1 | 2014 | 59 | 0.460 |
Why?
|
| Cardiomyopathies | 2 | 2016 | 547 | 0.460 |
Why?
|
| Fibroma | 1 | 2014 | 86 | 0.460 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 871 | 0.450 |
Why?
|
| Medical Oncology | 5 | 2020 | 1463 | 0.450 |
Why?
|
| Antineoplastic Agents | 10 | 2019 | 14636 | 0.430 |
Why?
|
| Vascular Diseases | 1 | 2015 | 235 | 0.410 |
Why?
|
| Aortic Aneurysm | 1 | 2014 | 218 | 0.400 |
Why?
|
| Cardiovascular Infections | 1 | 2012 | 9 | 0.400 |
Why?
|
| Sarcoma | 3 | 2023 | 1851 | 0.400 |
Why?
|
| Heart | 4 | 2023 | 1172 | 0.390 |
Why?
|
| Systole | 3 | 2016 | 217 | 0.390 |
Why?
|
| Osteosarcoma | 1 | 2019 | 951 | 0.390 |
Why?
|
| Diagnostic Imaging | 3 | 2018 | 1173 | 0.390 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2011 | 64 | 0.370 |
Why?
|
| Cardiac Tamponade | 3 | 2016 | 49 | 0.370 |
Why?
|
| Fluoroscopy | 1 | 2011 | 226 | 0.360 |
Why?
|
| Myocarditis | 1 | 2012 | 179 | 0.360 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2014 | 449 | 0.340 |
Why?
|
| Mass Screening | 1 | 2018 | 1554 | 0.340 |
Why?
|
| Tongue Neoplasms | 1 | 2012 | 253 | 0.340 |
Why?
|
| Quality Improvement | 1 | 2016 | 913 | 0.330 |
Why?
|
| Radiography, Interventional | 1 | 2011 | 311 | 0.330 |
Why?
|
| Humans | 64 | 2024 | 271093 | 0.330 |
Why?
|
| Multimodal Imaging | 4 | 2018 | 550 | 0.330 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 426 | 0.310 |
Why?
|
| Radiotherapy | 1 | 2015 | 1858 | 0.290 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2015 | 121 | 0.290 |
Why?
|
| Early Diagnosis | 3 | 2018 | 315 | 0.280 |
Why?
|
| Radiation Injuries | 1 | 2015 | 1475 | 0.280 |
Why?
|
| Trastuzumab | 5 | 2016 | 743 | 0.280 |
Why?
|
| Heart Failure | 4 | 2023 | 2322 | 0.270 |
Why?
|
| Coronary Artery Disease | 3 | 2021 | 884 | 0.260 |
Why?
|
| Male | 31 | 2024 | 128484 | 0.260 |
Why?
|
| Diastole | 2 | 2015 | 183 | 0.260 |
Why?
|
| Female | 35 | 2024 | 149120 | 0.250 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2004 | 172 | 0.250 |
Why?
|
| Stents | 1 | 2011 | 1002 | 0.250 |
Why?
|
| Middle Aged | 26 | 2022 | 90524 | 0.250 |
Why?
|
| Heart Conduction System | 2 | 2015 | 160 | 0.230 |
Why?
|
| Troponin I | 3 | 2015 | 131 | 0.230 |
Why?
|
| Ultrasonography | 5 | 2015 | 1929 | 0.230 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2004 | 112 | 0.220 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 24 | 0.220 |
Why?
|
| Risk Factors | 12 | 2024 | 17911 | 0.210 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2004 | 166 | 0.210 |
Why?
|
| Myocardial Infarction | 2 | 2015 | 1153 | 0.210 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2023 | 83 | 0.200 |
Why?
|
| Fatal Outcome | 2 | 2015 | 821 | 0.190 |
Why?
|
| Biomarkers | 7 | 2023 | 5054 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 80 | 0.190 |
Why?
|
| Predictive Value of Tests | 8 | 2022 | 4966 | 0.180 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 16238 | 0.180 |
Why?
|
| Radiation, Ionizing | 1 | 2020 | 190 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 322 | 0.170 |
Why?
|
| Shock, Septic | 1 | 2021 | 188 | 0.170 |
Why?
|
| Electrocardiography | 2 | 2015 | 1147 | 0.160 |
Why?
|
| Pericardiocentesis | 1 | 2019 | 36 | 0.160 |
Why?
|
| Catheters, Indwelling | 1 | 2021 | 382 | 0.160 |
Why?
|
| Erdheim-Chester Disease | 1 | 2018 | 55 | 0.150 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2018 | 42 | 0.150 |
Why?
|
| Myxoma | 1 | 2018 | 67 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 1 | 2023 | 462 | 0.150 |
Why?
|
| ROC Curve | 2 | 2021 | 1252 | 0.150 |
Why?
|
| Adult | 16 | 2024 | 82174 | 0.150 |
Why?
|
| Carcinoid Heart Disease | 1 | 2017 | 12 | 0.140 |
Why?
|
| Echocardiography, Doppler | 1 | 2018 | 186 | 0.140 |
Why?
|
| Prognosis | 9 | 2023 | 22529 | 0.140 |
Why?
|
| Staphylococcus aureus | 1 | 2021 | 564 | 0.140 |
Why?
|
| Retrospective Studies | 14 | 2022 | 39951 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2024 | 745 | 0.140 |
Why?
|
| Pericarditis, Constrictive | 1 | 2016 | 9 | 0.130 |
Why?
|
| Academies and Institutes | 1 | 2016 | 97 | 0.130 |
Why?
|
| Oligopeptides | 1 | 2018 | 450 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 674 | 0.130 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2024 | 741 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 5594 | 0.130 |
Why?
|
| Cardiotoxins | 1 | 2015 | 16 | 0.130 |
Why?
|
| Staphylococcal Infections | 1 | 2021 | 681 | 0.130 |
Why?
|
| Doxorubicin | 3 | 2023 | 3146 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 155 | 0.120 |
Why?
|
| Cefazolin | 1 | 2014 | 27 | 0.120 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 33 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 536 | 0.120 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2014 | 25 | 0.120 |
Why?
|
| Daptomycin | 1 | 2014 | 39 | 0.120 |
Why?
|
| Hypertension | 1 | 2004 | 1588 | 0.120 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 6191 | 0.120 |
Why?
|
| Cardiotonic Agents | 1 | 2016 | 155 | 0.120 |
Why?
|
| Aged | 14 | 2022 | 73550 | 0.120 |
Why?
|
| Myocardial Ischemia | 1 | 2018 | 400 | 0.120 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 250 | 0.110 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 3240 | 0.110 |
Why?
|
| Pericardium | 1 | 2015 | 147 | 0.110 |
Why?
|
| Dexmedetomidine | 1 | 2014 | 86 | 0.110 |
Why?
|
| Peroxidase | 1 | 2013 | 131 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2015 | 176 | 0.110 |
Why?
|
| Lung Neoplasms | 4 | 2020 | 12040 | 0.110 |
Why?
|
| Comorbidity | 3 | 2019 | 2394 | 0.100 |
Why?
|
| Myocardium | 1 | 2018 | 1175 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2021 | 15282 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 342 | 0.100 |
Why?
|
| Decision Trees | 1 | 2012 | 181 | 0.100 |
Why?
|
| Amyloidosis | 1 | 2014 | 174 | 0.100 |
Why?
|
| Texas | 4 | 2021 | 6452 | 0.100 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 345 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1740 | 0.100 |
Why?
|
| Aortic Valve | 1 | 2014 | 443 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2016 | 380 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2014 | 305 | 0.090 |
Why?
|
| Young Adult | 4 | 2024 | 22293 | 0.090 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 216 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2011 | 5165 | 0.090 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 2811 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 5775 | 0.090 |
Why?
|
| Endocarditis, Bacterial | 1 | 2012 | 152 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2015 | 606 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2023 | 2882 | 0.090 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 674 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 5581 | 0.090 |
Why?
|
| Preoperative Care | 2 | 2015 | 1580 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2011 | 242 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2019 | 1338 | 0.080 |
Why?
|
| Postoperative Complications | 2 | 2015 | 5679 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 453 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 2178 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 16720 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 3416 | 0.080 |
Why?
|
| Incidence | 4 | 2021 | 5841 | 0.080 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 1341 | 0.070 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 1260 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 4006 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2018 | 2325 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2018 | 6780 | 0.070 |
Why?
|
| Hodgkin Disease | 1 | 2015 | 1485 | 0.070 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 2028 | 0.060 |
Why?
|
| Antiviral Agents | 1 | 2012 | 1253 | 0.060 |
Why?
|
| Survival Rate | 4 | 2021 | 12535 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 2198 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 32784 | 0.060 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 254 | 0.060 |
Why?
|
| Animals | 5 | 2023 | 61554 | 0.060 |
Why?
|
| Radiosurgery | 1 | 2013 | 1384 | 0.060 |
Why?
|
| Aged, 80 and over | 5 | 2015 | 31079 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 85 | 0.050 |
Why?
|
| Prevalence | 1 | 2011 | 3412 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 7046 | 0.050 |
Why?
|
| Pulmonary Circulation | 1 | 2023 | 132 | 0.050 |
Why?
|
| Ventricular Function, Right | 1 | 2023 | 116 | 0.050 |
Why?
|
| Ribose | 1 | 2021 | 32 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 100 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2015 | 327 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 162 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 9039 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 293 | 0.050 |
Why?
|
| Feedback | 1 | 2021 | 225 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2018 | 33808 | 0.040 |
Why?
|
| Palliative Care | 1 | 2012 | 2175 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 3197 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 383 | 0.040 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 117 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2019 | 125 | 0.040 |
Why?
|
| United States | 4 | 2019 | 15891 | 0.040 |
Why?
|
| Taxoids | 2 | 2013 | 1019 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 418 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 585 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2024 | 696 | 0.040 |
Why?
|
| Societies | 1 | 2018 | 38 | 0.040 |
Why?
|
| Peptide Fragments | 2 | 2015 | 1306 | 0.040 |
Why?
|
| Program Development | 1 | 2019 | 259 | 0.040 |
Why?
|
| Interprofessional Relations | 1 | 2019 | 209 | 0.040 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2018 | 149 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 719 | 0.030 |
Why?
|
| Reference Values | 1 | 2018 | 1129 | 0.030 |
Why?
|
| Logistic Models | 2 | 2015 | 3445 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2019 | 602 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1135 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 400 | 0.030 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 238 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 4326 | 0.030 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2015 | 26 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 121 | 0.030 |
Why?
|
| Cytokines | 1 | 2023 | 2805 | 0.030 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 34 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 1292 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 2403 | 0.030 |
Why?
|
| Galectin 3 | 1 | 2015 | 131 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2016 | 312 | 0.030 |
Why?
|
| Ohio | 1 | 2014 | 117 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 1150 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 3244 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 4906 | 0.030 |
Why?
|
| Amyloid | 1 | 2014 | 91 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2022 | 13445 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 2014 | 273 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2015 | 352 | 0.030 |
Why?
|
| Europe | 1 | 2014 | 658 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 881 | 0.030 |
Why?
|
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 28 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 1990 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1852 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 4642 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 4020 | 0.020 |
Why?
|
| Global Health | 1 | 2017 | 691 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 556 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 588 | 0.020 |
Why?
|
| North America | 1 | 2012 | 341 | 0.020 |
Why?
|
| Mice | 2 | 2023 | 35477 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 2012 | 286 | 0.020 |
Why?
|
| Acute Disease | 1 | 2016 | 2492 | 0.020 |
Why?
|
| SEER Program | 1 | 2015 | 1052 | 0.020 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 624 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3488 | 0.020 |
Why?
|
| Anesthesia | 1 | 2014 | 298 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 1092 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6503 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 2311 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 2051 | 0.020 |
Why?
|
| Recurrence | 1 | 2018 | 4880 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 1112 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1310 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 2853 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2395 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 12991 | 0.020 |
Why?
|
| Radiology | 1 | 2014 | 426 | 0.020 |
Why?
|
| Age Factors | 1 | 2018 | 5458 | 0.020 |
Why?
|
| Breast | 1 | 2015 | 1369 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 902 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2014 | 1320 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 3846 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 2032 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 4503 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 6258 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 7900 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2013 | 9479 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2001 | 748 | 0.010 |
Why?
|
| Mitral Valve | 1 | 2001 | 266 | 0.010 |
Why?
|
| Probability | 1 | 2001 | 887 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 14020 | 0.010 |
Why?
|
| Observer Variation | 1 | 2001 | 710 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 4392 | 0.010 |
Why?
|